New drug combo shows promise in shrinking esophageal tumors before surgery
NCT ID NCT07385001
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of an immunotherapy drug (ivonescimab) with two chemotherapy drugs before surgery for people with a certain type of advanced esophageal cancer. The goal is to see if this approach can shrink tumors enough to improve long-term outcomes. About 45 adults with resectable, locally advanced esophageal squamous cell carcinoma will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tangdu Hospitial
RECRUITINGXi'an, Shannxi, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••